Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

CAL101

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Intravenous (IV) Injection

Funder Type:

Industry

Drug Details

CAL101 is an investigational, intravenously administered drug designed to block the activity of protein called S100A4, which is linked to lung scarring.

Study Purpose

This study is a randomized, double-blind, phase 2, placebo-controlled study on the safety and efficacy of CAL101 in participants with idiopathic pulmonary fibrosis (IPF).

Find a clinical trial